Strain Name: |
129S.B6-Tg(KRT14-Esr1/HRAS)1Pkha/J |
|---|---|
Stock Number: |
006403 |
Availability: | Repository-Cryopreserved |
General Terms and Conditions |
| Genes & Alleles | Esr1; HRAS; KRT14; Tg(KRT14-Esr1/HRAS)1Pkha; |
Type JAX® GEMM® Strain - Congenic Additional information on JAX® GEMM® Strains. Type JAX® GEMM® Strain - Mutant Strain Type JAX® GEMM® Strain - Transgenic Species laboratory mouse Donating Investigator Paul Khavari, Stanford University Generation N6pN1 Strain Description
Mice hemizygous for this "K14-ER:Ras" transgene are viable and fertile. Inducible expression of the ER:Ras fusion protein is observed in the epidermis following topical application of 4-hydroxytamoxifen (4OHT). Prolonged (4 weeks) induction of human H-RasG12V activity promotes the undifferentiated, proliferative phenotypic characteristics observed in epidermal cancer; including hyperplasia, increased mitotic index, decreased expression of differentiation markers and increased expression of beta-1 and beta-4 integrin subunits. H-RasG12V-induced skin abnormalities were entirely reversed within one month after 4OHT cessation. These mice have a similar 4OHT-inducible skin phenotype as the transgenic mice expressing human Raf-1[DD] (Stock No. 006661) or human Mek1R4F (Stock No. 006822), and may be useful in studies of the Ras/Raf/MEK/ERK cell proliferation and differentiation pathway, as well as to elucidate cellular events preceding skin cancer cell transformation.Strain Development
The ?K14-ER:Ras? transgene was designed with a 2075-bp human keratin 14 promoter sequence upstream of the constitutively active G12V mutant form of the catalytic domain of human H-ras (H-rasV12) fused at its amino terminal with the G525R mutant murine estrogen receptor ligand binding domain (ERTM), which renders transgene expression tamoxifen (4OHT) inducible yet estrogen insensitive. This transgene was injected into the pronuclei of C57BL/6 embryos and chimeric founders were established. Mice were then backcrossed to ?129/SvEv? mice for 5 generations prior to arrival at The Jackson Laboratory.
Mammalian Phenotype Terms assigned by genotype |
| Allele Symbol | Tg(KRT14-Esr1/HRAS)1Pkha | ||
|---|---|---|---|
| Allele Name | transgene insertion 1, Paul A Khavari | ||
| Common Name(s) | K14-ER:Ras; | ||
| Mutation Made By | Paul Khavari, Stanford University | ||
| Strain of Origin | C57BL/6 | ||
| Expressed Gene | Esr1, estrogen receptor 1 (alpha), mouse, laboratory | ||
| Expressed Gene | HRAS, v-Ha-ras Harvey rat sarcoma viral oncogene homolog, human | ||
| Promoter | KRT14, keratin 14 (epidermolysis bullosa simplex, Dowling-Meara, Koebner), human | ||
| General Note | Multiple mouse lines were generated, with varying transgene copy numbers and expression levels of the fusion protein. Lines were identified only as H, M, and L for high, medium and low copy number, respectively. | ||
| Molecular Note | The transgene contains a 2075-bp human keratin 14 promoter construct driving expression of a cDNA that encodes a fusion protein comprising a constitutively active mutant form of the catalytic domain of human HRAS, in which glycine at amino acid position12 is replaced by arginine (G12V), joined at its amino terminal to a mutant mouse estrogen receptor ligand-binding domain in which replacement of glycine by arginine at amino acid position 525 (G525R, "ERTM") renders the fusion protein's activity inducible by 4-hydroxytamoxifen, but unresponsive to natural estrogen (17beta-estradiol). [MGI Ref ID J:118583] [MGI Ref ID J:118586] [MGI Ref ID J:118587] [MGI Ref ID J:55801] [MGI Ref ID J:81660] | ||
| Control | ||
|---|---|---|
| Noncarrier | ||
| 002448 129S1/SvImJ | (approximate) | |
| Considerations for Choosing Controls | ||
Tg(KRT14-Esr1/HRAS)1Pkha
| Breeding & Husbandry | When maintaining a live colony, hemizygotes are bred to wildtype siblings or to inbred 129S1/SvImJ (Stock No. 002448) mice. |
|---|
Strains carrying other alleles of Esr1
004744 B6.129P2-Esr1tm1Ksk/J 004682 B6.Cg-Tg(CAG-cre/Esr1)5Amc/J 005657 B6.Cg-Tg(Myh6-cre/Esr1)1Jmk/J 005650 B6129-Tg(Myh6-cre/Esr1)1Jmk/J 006774 FVB-Tg(Col2a1-cre/ESR1)KA3Smac/J 006822 FVB-Tg(KRT14-MAP2K1/Esr1)12Pkha/J 004453 STOCK Tg(CAG-cre/Esr1)5Amc/J 008122 STOCK Tg(Ins2-cre/Esr1)1Dam/J 005107 STOCK Tg(KRT14-cre/Esr1)20Efu/J 008119 STOCK Tg(Neurog3-cre/Esr1)1Dam/J View Strains carrying other alleles of Esr1 (10 strains)
Strains carrying other alleles of HRAS
002409 B6;SJL-Tg(Wap-HRAS)69Lln Chr YSJL/J 002410 FVB.Cg-Tg(Wap-HRAS)69Lln Chr YSJL/J View Strains carrying other alleles of HRAS (2 strains)
Strains carrying other alleles of KRT14
006661 129S.B6-Tg(KRT14-RAF1/ESR1)1Pkha/J 004853 B6.C3-Tg(KRT14-Birc5)19Gros/J 007622 B6;SJL-Tg(KRT14-Hr)551Cct/J 007678 B6;SJL-Tg(KRT14-rtTA)208Jek/J 002980 C57BL/6-Tg(Cd152Ig)1Jbs/J 006822 FVB-Tg(KRT14-MAP2K1/Esr1)12Pkha/J 005705 FVB-Tg(KRT14-Vegfa)3Dtm/J 008099 FVB-Tg(KRT14-rtTA)F42Efu/J 004782 STOCK Tg(KRT14-cre)1Amc/J 005107 STOCK Tg(KRT14-cre/Esr1)20Efu/J View Strains carrying other alleles of KRT14 (10 strains)
Congenic Nomenclature
HRAS relatedCancer Research
Genes Regulating Growth and Proliferation
Other
Cell Biology Research
Genes Regulating Growth and Proliferation
Signal Transduction
Dermatology Research
Other
Research Tools
Cancer Research
Cell Biology Research
Dermatology Research
Cancer Research
Increased Tumor Incidence (Mammary Gland Tumors: males only)
Oncogenes
Selected Reference(s)
Additional ReferencesTarutani M; Cai T; Dajee M; Khavari PA. 2003. Inducible activation of ras and raf in adult epidermis. Cancer Res 63(2):319-23. [PubMed: 12543782] [MGI Ref ID J:81660]
| Strain Name: | 129S.B6-Tg(KRT14-Esr1/HRAS)1Pkha/J |
| Stock Number: | 006403 |
IMPORTANT NOTE: Prices are based on shipping destination. To view prices, select your shipping destination.
| Standard Supply | Repository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
Cryorecovery - Standard. The recovery process begins when a signed agreement form is returned to the Customer Service Department after order placement. Although results vary by strain, at least two males and two females (two pairs) will be provided, typically within 15 weeks of our receipt of the signed agreement form. If the first recovery attempt is unsuccessful or only one pair is recovered, a second recovery will be done, extending the delivery time to approximately 25 weeks. At least one member of each pair will be of known genotype and will carry the mutation if it is a mutant strain. Please note that pairs may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation of the strain. Mating schemes are sometimes modified for successful cryopreservation. Price represents a repository maintenance fee, which includes the cost of recovery of the strain from the cryopreservation resource and the periodic replacement of the frozen embryos used for recovery. Cryorecovery to establish a Dedicated Supply for greater quantities of mice. |
| Licensing | See General Terms and Conditions below for Licensing and Use Restrictions |
| Control Information | View Control Information in Strain Details. |
For additional Licensing and Use Restrictions view the link(s) below:
- Notice Regarding cre/Esr1 (Tamoxifen Inducible Cre) Strains.
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form